Teva: Chancen und Risiken bei Generika

Heute schreibt Georg Thilenius über Generika und speziell über Teva
"Schwankend, aber gewinnträchtig"
http://www.manager-magazin.de/geld/artikel/0,2828,389536,00.html

Der indische Generika-Hersteller Ranbaxy erlebte im Oktober nach einem gewaltigen Gewinneinbruch auch einen starken Kurseinbruch.
In der Einschätzung "equal-weight" für Ranbaxy von Morgan Stanley Ende Oktober heißt es: "Das schlechte Ergebnis hänge in erster Linie mit dem sich verschlechternden operativen Umfeld in den Vereinigten Staaten zusammen."

Was ist nun der Unterschied, dass Thilenius Generika und Teva so viel besser sieht ?
Er erweckt den Eindruck, als gehe es zwar auf und ab, aber unter dem Strich gehe der Trend nach oben.
Die Realität ist aber anscheinend, dass dies eine Branche ist, wo es viel auf die Entscheidungen bei Gerichtsverhandlungen ankommt, vgl. Meldung vom 22.11.05 "AstraZeneca verklagt Ranbaxy".

 

Die Bank of America reduziert ihr Kursziel für Teva von 45$ auf 35$, siehe
http://www.newratings.com/analyst_news/article_1273534.html  

Teva Gets FDA OK For Ondansetron Injection USP 11-22-06

02:11 PM EST
DOW JONES NEWSWIRES

Teva Pharmaceutical Industries Ltd. (TEVA) said Wednesday the Food and Drug Administration has granted final approval for Ondansetron injection, the generic version of GlaxoSmithKline Plc's (GSK) Zofran.

Shipments of Ondansetron products will begin immediately, Israel-based Teva said.

The drug is used to treat vomiting and nausea.

Zofran had annual sales of $695 million for the 12 months ended September 2006, Teva said, citing IMS sales data.

-Gabriel Madway; 415-439-6400; AskNewswires@dowjones.com


(END) Dow Jones Newswires
11-22-06 1411ET
Copyright (c) 2006 Dow Jones & Company, Inc.  

Greetings & Shalom,
meistgehandeltste Aktie heute TEVA
+1,8% zu 158,5 shekel = 37,37$

in NY am Dienstag 36,95$ jetzt RT= 37,93=+2,65%%%%%

am Dienstag erklärt TEVA + 51% VK +63% h^her Verkauf (inkl Ivax Artikel)

Citigroup hi risk = BUY 2007 top pick target 46$
(Copaxone MS Verkauf, +++

Merril Lynch = bullish +++

Clal Finance = outperform target 43$

WR Hambrecht = 40$ ++

IBI Invest = target +45$++

... Tel Aviv riesige Volumina, Tel Aviv Allzeithoch,

NY RT Vol 7054623t

 

Teva mit kräftigem Umsatz- und Gewinnwachstum
Petach Tikva (aktiencheck.de AG) - Der israelische Generika-Hersteller Teva Pharmaceutical Industries Ltd. (ISIN US8816242098/ WKN
Leser des Artikels: 24


Petach Tikva (aktiencheck.de AG) - Der israelische Generika-Hersteller Teva Pharmaceutical Industries Ltd. (ISIN US8816242098/ WKN 880035) konnte im Schlussquartal 2006 einen kräftigen Anstieg bei Umsatz und Ergebnis verzeichnen.


Wie der Konzern am Dienstag mitteilte, zogen die Umsatzerlöse auf 2,28 Mrd. Dollar an, nach 1,40 Mrd. Dollar im Vorjahresquartal. Dies stellt eine Steigerung um 63 Prozent dar.


Ferner kletterte der Nettogewinn um 51 Prozent von 305 Mio. Dollar oder 45 Cents im vierten Quartal 2005 auf nun 460 Mio. Dollar bzw. 56 Cents pro Aktie. Mit 53 Cents lag das um Sondereffekte bereinigte EPS damit unter der durchschnittlichen Analystenprognose von 58 Cents.


Für das laufende erste Quartal 2007 rechnen Analysten durchschnittlich mit einem Gewinn pro Aktie in Höhe von 52 Cents bei Umsätzen von 2,17 Mrd. Dollar.


Gestern stiegen die Aktien um 1,03 Prozent und schlossen bei 35,36 Dollar. (13.02.2007/ac/n/a)  

Teva Shares Jump on 4Q Profit, Outlook

Shares of generic drug developer Teva Pharmaceuticals Ltd. jumped Wednesday, a day after the company reported a 51 percent increase in its fourth-quarter profit.

The stock gained $1.01, or 2.7 percent, to close at $37.96 on the Nasdaq. Shares have traded between $29.22 and $43.90 over the last 52 weeks.

Early Tuesday, the company reported a jump in profit to 56 cents per share, as revenue surged 63 percent on sales of new products, including the antidepressants Bupropion XL and Venlafaxine. Revenue also was augmented by products gained from the company's $7 billion buyout of Ivax Corp. in January 2006.

Analysts reaffirmed positive ratings for the company Wednesday, citing Teva's forecast for growth over the next several years.

Deutsche Bank (nyse: DB - news - people ) analyst David M. Steinberg reaffirmed a "Buy" rating with a $45 price target.

"Central to the business outlook, Teva continues to boast the most impressive generic product pipeline in the entire global pharmaceutical industry," he wrote in a note to investors.

He said the company expects growth in 2007, with more than $9 billion in projected revenue, to be driven by 30 to 40 smaller products, and large generic opportunities in 2008 will drive growth even further. The company also will regain full Copaxone rights from Sanofi-Aventis (nyse: SNY - news - people ) in 2008. It will pay Sanofi-Aventis 25 percent on revenue from the multiple sclerosis drug for the first two years. The payments will end in 2010.

"For 2008 and beyond, we continue to see solid earnings per share growth re-emerging," he said.

Citigroup (nyse: C - news - people ) analyst Robert Bonte-Friedheim reaffirmed a "Buy" rating and a $46 price target, citing the outlook and possibility for a pathway to make future generic biotechnology drugs.

Lehman Brothers (nyse: LEH - news - people ) analyst Richard Silver reaffirmed a "Overweight" rating with a $43 price target.

"Our hope is that transparency will continue to improve in the coming quarters - in particular, with greater insight and commentary on European and international business trends, given the increasing importance of these non-U.S. growth drivers," he said  

Teva in running to buy largest Turkish drug co. - report
Turkish daily “Aksam”: “Teva is one of the bidders for local drug company Eczacibasi.”
Gil Shlomo 22 Feb 07   12:37
Turkish newspaper “Aksam” reported this morning that Teva Pharmaceutical Industries Ltd. (Nasdaq: TEVA; TASE: TEVA) and Sanofi Aventis are among the companies interested in acquiring Turkish drug company Eczacibasi Ilac Sanayi & Ticaret AS. However, the newspaper did not name its source.

“Aksam” said that Eczacibasi, Turkey’s largest drug maker, announced in January that it aims to sell at least half its pharmaceutical business and that it had hired Merrill Lynch to help it find a buyer. Eczacibasi reported annual sales of $2.8 billion. It controls 38 related companies and employs 8,500 people.  

Teva posts first-quarter profit vs year-ago loss
Wed May 2, 2007 12:23

May 2 (Reuters) - Teva Pharmaceutical Industries Ltd., the world's largest generic drugmaker, posted a profit in the first-quarter compared with a year-ago loss, helped by strong demand for generic products across all geographies.

Quarterly net income at the Israel-based company was $342 million, or 42 cents per share, compared with a net loss of $1.0 billion, or $1.40 per share, a year earlier.

Excluding items, Teva earned 42 cents per share, compared with 37 cents, a year-ago.

Teva was expected to earn 39 cents a share on a GAAP basis and 40 cents a share, excluding items, according to Reuters Estimates.

Sales rose to $2.08 billion from $1.67 billion. (Reporting by Dilipp S. Nag in Bangalore)